European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease - The substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow by Meulenbroek, Olga et al.

Title European multicentre double-blind placebo-controlled trial of
Nilvadipine in mild-to-moderate Alzheimer's disease - The substudy
protocols: NILVAD frailty; NILVAD blood and genetic biomarkers;
NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow
Author(s) Meulenbroek, Olga; O'Dwyer, Sarah; de Jong, Daan; van Spijker,
Gerrita; Kennelly, Sean; Cregg, Fiona; Olde Rikkert, Marcel; Abdullah,
Laila; Wallin, Anders; Walsh, Cathal; Coen, Robert; Kenny, Rose Anne;
Daly, Leslie; Segurado, Ricardo; Borjesson-Hanson, Anne; Crawford,
Fiona; Mullan, Michael; Lucca, Ugo; Banzi, Rita; Pasquier, Florence;
Breuilh, Laetitia; Riepe, Matthias; Kalman, Janos; Molloy, D. William;
Tsolaki, Magda; Howard, Robert; Adams, Jessica; Gaynor, Siobhan;
Lawlor, Brian A.
Publication date 2016-05-04
Original citation Meulenbroek, O., O'Dwyer, S., de Jong, D., van Spijker, G., Kennelly,
S., Cregg, F., Olde Rikkert, M., Abdullah, L., Wallin, A., Walsh, C.,
Coen, R., Kenny, R. A., Daly, L., Segurado, R., Borjesson-Hanson, A.,
Crawford, F., Mullan, M., Lucca, U., Banzi, R., Pasquier, F., Breuilh, L.,
Riepe, M., Kalman, J., Molloy, W., Tsolaki, M., Howard, R., Adams, J.,
Gaynor, S. and Lawlor, B. (2016) 'European multicentre double-blind
placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's
disease—the substudy protocols: NILVAD frailty; NILVAD blood and
genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD
cerebral blood flow', BMJ Open, 6(7) e011584 (13pp). doi:
10.1136/bmjopen-2016-011584
Type of publication Article (peer-reviewed)
Link to publisher's
version
http://bmjopen.bmj.com/content/6/7/e011584
http://dx.doi.org/10.1136/bmjopen-2016-011584
Access to the full text of the published version may require a
subscription.
Rights Published by the BMJ Publishing Group Limited. For permission to
use (where not already granted under a licence) please go to
http://www.bmj.com/company/products-services/rights-and-
licensing/ This is an Open Access article distributed in accordance
with the Creative Commons Attribution Non Commercial (CC BY-
NC 4.0) license, which permits others to distribute, remix, adapt,
build upon this work non-commercially, and license their derivative
works on different terms, provided the original work is properly
cited and the use is non-commercial. See:
http://creativecommons.org/licenses/by-nc/4.0/
https://creativecommons.org/licenses/by-nc/4.0/
Item downloaded
from
http://hdl.handle.net/10468/4172
Downloaded on 2017-09-05T01:05:13Z

European multicentre double-blind
placebo-controlled trial of Nilvadipine
in mild-to-moderate Alzheimer’s
disease—the substudy protocols:
NILVAD frailty; NILVAD blood and
genetic biomarkers; NILVAD
cerebrospinal ﬂuid biomarkers;
NILVAD cerebral blood ﬂow
Olga Meulenbroek,1 Sarah O’Dwyer,2 Daan de Jong,1 Gerrita van Spijker,1
Sean Kennelly,3 Fiona Cregg,3 Marcel Olde Rikkert,1 Laila Abdullah,4
Anders Wallin,5 Cathal Walsh,6 Robert Coen,2 Rose Anne Kenny,2 Leslie Daly,6
Ricardo Segurado,6 Anne Borjesson-Hanson,5 Fiona Crawford,7 Michael Mullan,7
Ugo Lucca,8 Rita Banzi,8 Florence Pasquier,9 Laetitia Breuilh,9 Matthias Riepe,10
Janos Kalman,11 William Molloy,12 Magda Tsolaki,13 Robert Howard,14
Jessica Adams,14 Siobhan Gaynor,15 Brian Lawlor2To cite: Meulenbroek O,
O’Dwyer S, de Jong D, et al.
European multicentre double-
blind placebo-controlled trial
of Nilvadipine in mild-to-
moderate Alzheimer’s disease
—the substudy protocols:
NILVAD frailty; NILVAD blood
and genetic biomarkers;
NILVAD cerebrospinal fluid
biomarkers; NILVAD cerebral
blood flow. BMJ Open
2016;6:e011584.
doi:10.1136/bmjopen-2016-
011584
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2016-011584).
Received 19 February 2016
Accepted 4 May 2016
For numbered affiliations see
end of article.
Correspondence to
Professor Brian Lawlor;
blawlor@stjames.ie
ABSTRACT
Introduction: In conjunction with the NILVAD trial, a
European Multicentre Double-Blind Placebo Controlled
trial of Nilvadipine in Mild-to-Moderate Alzheimer’s
disease (AD), there are four NILVAD substudies in
which eligible NILVAD patients are also invited to
participate. The main NILVAD protocol was previously
published in BMJ Open (2014). The objectives of the
NILVAD substudies are to determine whether frailty,
cerebrospinal fluid (CSF), blood biomarker
profile and Apolipoprotein E (APOE) status predict
response to Nilvadipine, and to investigate the effect of
Nilvadipine on cerebral blood flow and blood
biomarkers.
Methods and analysis: All participants who fulfil
criteria for the main NILVAD study are eligible for
participation in the NILVAD substudies. Participation is
subject to informed consent and whether the substudy
is available at a particular NILVAD study site. Each
substudy entails extra measurements during the course
of the main NILVAD study. For example, in the blood
and genetic biomarkers substudy, extra blood (30 mL)
will be collected at week 0, week 13, week 52 and
week 78, while in the cerebral blood flow substudy,
participants will receive an MRI and transcranial
Doppler measurements at week 0, week 26 and week
78. In the CSF substudy, 10 mL CSF is collected at
week 0 and week 78.
Ethics and dissemination: All NILVAD substudies
and all subsequent amendments have received ethical
approval within each participating country, according to
national regulations. Each participant provides written
consent to participate. All participants remain
anonymised throughout and the results of each
substudy will be published in an international peer
reviewed journal.
Trial registration number: EUDRACT 2012-002764-
27; Pre-results.
Strengths and limitations of this study
▪ These nested NILVAD substudies will collect
biomarker data to determine if biomarker status
predicts response to Nilvadipine.
▪ The substudies run in parallel with the main
NILVAD trial and thus facilitate the collection of
data.
▪ This biomarker data collection in
mild-to-moderate Alzheimer’s disease (AD) will
provide valuable insight into the in vivo effects
of Nilvadipine on these parameters. In addition,
these studies provide the opportunity to study
the relationship between the different outcome
measures.
▪ The substudies will not necessarily be completed
by all participants recruited for the main NILVAD
study (500 participants). Therefore, the results
are potentially less generalisable compared to
the main NILVAD study. For example, the cere-
bral blood flow substudy will only run in one
study site and aims to recruit 40 patients.
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INTRODUCTION
The NILVAD study is a large European multicentre, ran-
domised, double-blind, placebo-controlled trial investi-
gating the efﬁcacy and safety of Nilvadipine as a disease
course modifying treatment in mild to moderate
Alzheimer’s disease (AD). As part of this trial, four
nested substudies have been developed to investigate if
frailty status, cerebrospinal ﬂuid (CSF) and blood bio-
marker proﬁles, and Apolipoprotein (APOE) status can
predict response to Nilvadipine. Furthermore, the in
vivo effects of Nilvadipine on frailty, cerebral blood ﬂow
and blood biomarker status over time will be deter-
mined. The substudies have also been designed to
examine other end points that are relevant to AD
pathology and allow assessment of AD progression. The
four substudies are detailed as follows.
Frailty substudy
Frailty is a common and important syndrome that is
increasingly prevalent with advancing age. A consensus
view is emerging where the physical phenotype of frailty
develops as a consequence of complex biological interac-
tions that promote cell senescence, leading to a cumula-
tive decline in multiple physiological systems,
particularly the brain, endocrine system, immune
systems and skeletal muscles. Furthermore, there is accu-
mulating evidence to support a temporal association
between frailty, cognitive impairment and dementia.1 2
It has been suggested that frailty can be used as an
outcome measure because of its relationship with sur-
vival and adverse outcomes such as hospitalisation in
older adults.3
Thus, a substudy to measure frailty was developed
aiming (1) to investigate whether baseline frailty status
predicts response to treatment with Nilvadipine and (2)
to determine if treatment with Nilvadipine inﬂuences
frailty status. Frailty will be measured via gait speed and
a frailty index.
A large study by Fried et al,4 investigating frailty in
older adults, operationalised frailty using a cluster of
variables: unintentional weight loss, self-reported exhaus-
tion, low energy expenditure, weak grip strength and
slow gait speed. Their study provided the basis for identi-
fying frailty phenotypes to predict outcome. Rockwood
et al5 found that slow gait speed had the strongest associ-
ation with dependency, long-term care and death, indi-
cating gait speed might be a useful single indicator of
frailty. Therefore, gait speed was chosen as a prospective
physical marker of frailty in this substudy.
The Rockwood frailty index (FI) was developed from
part of the Canadian Study of Health and Ageing.5 It
consists of multiple parameters (‘deﬁcits’) that can be
measured, and allows for calculation of the presence or
absence of frailty (simple calculation of the presence or
absence of each variable as a proportion of the total: for
example, 20 deﬁcits present out of a possible 70 gives a
FI of 20/70=0.29). Older adults with a FI of ≤0.08 can
be considered non-frail, whereas those with an FI of
≥0.25 are considered frail. Considering that parameters
for the FI should be biologically sensible, accumulate
with age and do not saturate too early, a list of para-
meters will be collected to deﬁne a valid FI before,
during and after participation in the NILVAD study.6 7
They are extracted from existing questionnaires, includ-
ing the Disability Assessment of Dementia (DAD),
Alzheimer’s Disease Assessment Scale (ADAS-Cog 12),
the Lubben Social Network Scale (LSNS) and the
Charlson Comorbidity Index (CCI).8–11
We expect that if Nilvadipine has a positive effect on
cognition, it will also do so on frailty, with less deterior-
ation or with possible stabilisation.
Blood and genetic biomarkers substudy
Nilvadipine has been shown to have a multimodal
action, decreasing amyloid production in transgenic
mouse models of AD and increasing clearance of
amyloid across the blood-brain barrier (BBB) as well as
having anti-inﬂammatory effects in in vitro models.12–14
Thus, changes in amyloid and τ fragments along with
other inﬂammatory markers in the peripheral blood
from study baseline to end point may be useful in
improving our understanding of the biological effects of
Nilvadipine treatment in AD.
Levels of plasma Abeta (Aβ) and τ have been sug-
gested as possible biomarkers for detecting conversion
from normal cognition to mild cognitive impairment
(MCI) or AD.15 16 As such, measurement of plasma Aβ
and τ could be useful as potential biomarkers for detect-
ing disease-modifying therapeutic effects.
The APOE ε4 allele is one of the major genetic risk
factors for AD and occurs in nearly 60% of all AD
cases.17 Most studies investigating treatment strategies
for AD now include APOE testing to determine whether
treatment outcomes vary by genotype.18 In a study by
Kennelly et al,19 AD indicated that non-APOE ε4 carriers
showed more of a short-term beneﬁt from Nilvadipine
treatment than did ε4 carriers.
Recently, a broad lipidomic characterisation of other
phospholipids (PL) showed that a ratio of arachidonic
acid to docosahexaenoic acid (DHA) was increased
within several PL classes in APOE ε4 carriers several
years prior to diagnosis of MCI/AD.20 As such, we
expect that identiﬁcation of APOE status and monitor-
ing of these PL species could assist in monitoring effects
of Nilvadipine on AD progression.
Inﬂammation is an active component of AD pathology,
with aberrant activation of microglia and astroglia result-
ing in prolonged exposure to proinﬂammatory cyto-
kines, contributing to chronic neuroinﬂammation in the
brains of patients with AD. Studies have shown that
various proinﬂammatory cytokines are increased in
plasma and CSF in AD compared to in control sub-
jects.21 22 Preclinical work on Nilvadipine supports its
potential anti-inﬂammatory action and therefore exam-
ination of proinﬂammatory cytokines may be useful
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biomarkers in determining therapeutic response to
Nilvadipine.
The aim of this substudy is thus to determine whether
genetic inﬂuences can modify the effect of Nilvadipine
on AD pathogenesis and whether changes in plasma Aβ,
τ and inﬂammatory markers from study baseline to end
point are altered by Nilvadipine treatment.
CSF substudy
CSF biomarker levels of total τ (T), phosphorylated
τ (P) and β-amyloid 1-42 (Aβ1-42), reﬂect, respectively,
axonal nerve cell degeneration, formation of neuroﬁbril-
lary tangles and disturbed β-amyloid metabolism, thus
allowing identiﬁcation of neurodegenerative and cere-
brovascular disease mechanism. These biomarkers, T,
P-τ, Aβ and the Aβ-ratio, are considered to be most
closely associated with AD core pathology. A systematic
review of CSF biomarkers in AD, in 2003, demonstrated
a diagnostic speciﬁcity of ∼90% and a sensitivity of
∼80% for both T and P for AD.23 In addition, it has
been shown that the Aβ/τ ratio can be used to predict
the conversion of MCI to AD with a speciﬁcity of 85%
and a sensitivity of 86%.24 Although pure AD is often
regarded as the most common dementia, it is probably
less common than mixed dementia (MD: presence of
AD and small vessel disease).25 A different biomarker
pattern is characteristic of patients with manifest MD as
well as pure subcortical vascular dementia with increased
levels of neuroﬁlament light subunit, myelin basic
protein and tissue inhibitor of metalloproteinases,
reﬂecting disturbances of the subcortical regions.26 27
However, patients with mixed pathology also display
deviations in the AD-related biomarkers (Aβ1-42, T and
P), thus leaving these biomarkers ineffective in differen-
tiating between these patient groups.28
In conclusion, determination of CSF biomarkers may
be useful for enhanced diagnostic purposes to assess
which patients display signs of pure AD, mixed type
dementia or a more pure vascular proﬁle, with expect-
ation that the treatment response is larger in patients
with vascular involvement.
Thus the aim of this CSF substudy is to explore the
biomarker status of NILVAD participants at baseline as a
predictor of response to Nilvadipine and investigate bio-
marker changes over time, with Nilvadipine treatment,
possibly enhancing our understanding of the in vivo
effect of Nilvadipine.
Cerebral blood flow study
Animal models indicate that AD may be associated with
profound vascular changes.29 For example, cerebral
autoregulation—the mechanism that aims to stabilise
cerebral blood ﬂow during changes in blood pressure—
was severely impaired in the transgenic mouse model for
AD.30 Speciﬁcally, Aβ may lead to both, structural and
functional cerebrovascular changes that may result in an
increased risk for cerebral hypoperfusion and ischaemia.
A recent study found that Nilvadipine inhibited
vasoconstriction elicited by Aβ and restored decreased
cortical perfusion in a transgenic mouse model, overex-
pressing human Aβ.13 How AD affects the cerebral vascu-
lature and cerebral autoregulation in humans remains
poorly understood. Nilvadipine has been shown to sig-
niﬁcantly improve memory and regional cerebral blood
ﬂow (rCBF) deﬁcits in the left frontal lobe in hyperten-
sive patients with MCI, while amlodipine did not.31 In
fact, regional cerebral blood ﬂow in the temporal lobe
of the amlodipine group deteriorated. The rCBF and
cognitive effects were independent of the reduction in
systolic and diastolic blood pressure after treatment.
In addition to the potentially beneﬁcial cerebrovascu-
lar effects of Nilvadipine, it may also improve blood pres-
sure (BP), with variation in systolic BP shown to be
reduced by calcium-channel blockers (and non-loop
diuretic drugs), but increased by ACE inhibitors,
angiotensin-receptor blockers and β-blockers.32 Thus, BP
variability, a factor that may enhance risk of cerebral
ischaemia, could be reduced by Nilvadipine, more than
by other antihypertensive drugs.
Thus this CBF substudy will investigate the effects of
Nilvadipine on CBF, BP and BP variability in study parti-
cipants. It is expected that Nilvadipine treatment,
through direct systemic and cerebral vascular effects, will
beneﬁcially modulate these characteristics.
In summary, these substudies will provide information
on the effects of Nilvadipine on physical, cardiovascular
and blood ﬂow measures in AD. The substudies will also
determine whether biomarker and genetic status pre-
dicts response to Nilvadipine, and will provide clues to
the mechanism of action of Nilvadipine in AD. In add-
ition, NILVAD substudies will provide novel data on the
effects of Nilvadipine on frailty. Finally, the long-term
storage and retention of blood and CSF samples will
contribute signiﬁcantly to a unique bioresource for
studies of AD in the future.
METHODS AND ANALYSIS
Frailty substudy
Study design
Study participants will undergo a frailty assessment at
particular time points. The schedule consists of comple-
tion of the DAD, ADAS-Cog12, LSNS and CCI.
Collection of data variables from these assessments will
facilitate deﬁnition of a FI before, during and after par-
ticipation in the NILVAD study.
The main NILVAD study runs for a total of 82 weeks,
with 78 weeks of study drug treatment (Nilvadipine or
placebo). The LSNS and CCI (ﬁgure 1) are performed
at study baseline (week 0) and treatment end point
(week 78). The DAD and ADAS-Cog and gait speed
(ﬁgure 2) are performed at week 0, 13, 52 and 78.
Inclusion/exclusion criteria
The inclusion and exclusion criteria for this substudy
are as for the main NILVAD study.33
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Figure 1 Frailty assessment schedule. ADAS, Alzheimer’s Disease Assessment Scale; DAD, Disability Assessment of
Dementia.
Figure 2 Protocol for measuring gait speed.
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Recruitment
There are a total of 23 study sites in 9 participating
European countries. Recruitment for the substudies will
be undertaken locally at each study site according the
local guidelines and procedures relevant to that site. All
study sites will participate in the Frailty substudy, exclud-
ing Germany.
Consenting process
All consenting participants for the main NILVAD study
will be invited to also provide written consent to partake
in the substudies, with the option of consenting to par-
ticipate in as many of the substudies as they wish,
dependent on availability of the substudy at any given
study site. Consent will be obtained following a full
explanation of each substudy, its objectives, risks and
potential beneﬁts. A patient information leaﬂet and a
carer’s information leaﬂet will be provided at least 7 days
prior to obtaining written consent, to allow participants
and their carers time to consider enrolling. Written
consent will be obtained at the main NILVAD screening
visit, prior to the undertaking of any interventions or
assessments.
As per the consenting process for NILVAD, when a
participant has reduced decision-making capacity, the
procedure for obtaining consent must follow national
law and will be assessed by the relevant bodies in each of
the participating countries.
Sample size calculation
The FI ranges from 0 to 1, with a natural maximum of
0.7. To calculate the sample size, we conservatively
estimated the variance to be large, that is, a SD of 0.3.
A sample size of 140 is adequate to allow detection of a
10% difference in FI between the NILVAD (experimen-
tal) and placebo (control) groups, and facilitate rejec-
tion of the null hypothesis that the population means of
each group are equal with probability (power) 0.8. The
type I error probability associated with the test of this
null hypothesis is a two-sided α=0.05.
Data analysis
Data will be automatically drawn from an online Macro
system, using a script in Matlab (The Mathworks, Natick,
Massachusetts, USA). Then the FI will be calculated as a
weighted score based on items from the ADAS-Cog
(3 items), CCI (15 items), DAD (36 items), LSNS
(2 items) and the gait speed (1 item). Points scored per
visit are divided by the number of items applied at that
visit, resulting in a FI between 0 and 1.
First, an independent samples t–test will be used to
assess if there is a difference in FI between the groups at
baseline, using α=0.05 as signiﬁcance level. When the
scores do not differ signiﬁcantly, an independent
samples t–test will be used to assess if there is a differ-
ence in FI between the groups at week 78, using α=0.05
as signiﬁcance level. If the FI scores do differ at baseline
between the groups, the data will be analysed using a
mixed linear model (MLM), to examine whether
Nilvadipine treatment (independent ﬁxed factor)
altered repeat measurements of FI over time (outcome
factor) while controlling for random effects (each par-
ticipant), again using α=0.05 as signiﬁcance level.
The above analyses will be conducted on the ‘per
protocol population’ (those participants who have no
violations to the protocol for the duration of the study).
Blood and genetic biomarkers substudy
Study design
This substudy will involve collection of 30 mL of blood
for genetic and biomarker analysis at four time points:
week 0, week 13, week 52 and week 78. Whole blood
(1 mL) will be aliquoted for genotyping for APOE 4 at
week 0. The remaining 29 mL of the sample will be pro-
cessed for biomarker analysis as per the protocol stand-
ard operating procedure (SOP), for blood processing
and sample preparation (box 1).
All samples will be collected, aliquoted and stored
locally at each study site initially and then transported
for ﬁnal study analysis to a central study site, before
transfer to a biobank for long-term storage. All samples
will be stored under speciﬁc conditions and coded for
identiﬁcation according to the protocol SOP.
Inclusion/exclusion criteria
The inclusion and exclusion criteria for this substudy
are as for the main NILVAD study.33
Recruitment
All study sites will participate in the blood and bio-
marker substudy except for those based in the UK and
Germany.
Sample size calculations
Using the available serum data on decreases of Aβ40
observed in the phase I/II Nilvadipine study (unpub-
lished data), we calculated an effect-size of 0.08 (based
on the mean change from baseline to week 6 of the
study, and the variance of Aβ40 measurements within
treated and untreated participants). Given this effect
size, a sample size of 254 participants is proposed to
allow incorporation of 4 repeated samplings, to detect
statistical signiﬁcance at α=0.05 with a power of 90%.
Sample analysis
Pure Gene Kits (Gentra Systems, Minneapolis,
Minnesota, USA) will be used for extracting DNA from
whole blood and PCR analyses for APOE will be per-
formed using previously established methods.34 Blood
Aβ40 levels will be analysed as previously described,
using commercially available ELISA kits.35 Lipidomics
analysis on plasma lipid extracts will be performed using
LC/MS analyses previously described.34 36 Serum levels
of proinﬂammatory cytokines, such as tumour necrosis
factor-α and IL-1β, will be examined using high-
sensitivity ELISA kits as per manufacturer’s instructions.
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Data analysis
A MLM will also be employed to examine whether
Nilvadipine treatment (independent ﬁxed factor)
altered repeat measurements of blood biomarkers over
time (outcome factor) while controlling for random
effects (each partcipant). MLM-based regression analysis
is generally considered advantageous over other analysis
of variance ANOVA due to its ﬂexibility to accommodate
ﬁxed and random effects of the independent variables
as well as incorporate dichotomous, continuous and
categorical variables.37 For lipidomics analyses, principal
component analysis (PCA) followed by MLM regression
will be performed as described previously.36 Brieﬂy,
dimension reduction and multicolinearity issues will be
resolved using PCA.
In order to ensure sampling adequacy for PCA, ana-
lysis achieving Kaiser- Mayer- Olkin (KMO) value of >0.6
and Bartlett p value <0.05 will be further investigated.
Variables with eigenvalues of >1 will be retained, PCA
will be used for extracting components and varimax with
Box 1 Standard operating procedure for blood processing for genotyping and biomarker analysis
Sample collection
▸ For each participant, at week 0, week 13, week 52 and week 78 visit, draw a minimum of: 2×10 mL EDTA tubes for plasma.
▸ Use a ×10 mL serum separator tube (with silica plug) for serum.
▸ Obtain blood samples via standard phlebotomy procedures. Please follow the guidelines from your facility for performing these
procedures.
▸ Draw the correct volume of blood allowing the vacuum in the tube to be exhausted.
▸ Gently invert each tube to mix immediately following blood collection.
▸ Process blood samples for genotyping, plasma and serum immediately on collection.
▸ It is vital that blood samples are processed immediately as the biomarker proteins start to degrade if they are left for any length of time
before processing.
Whole blood for genotyping (only to be carried out at week 0)
▸ Label one 1.5 mL polypropylene cryovial per patient, with a biobanking label. This label should contain the Biobank ID, the visit number,
the sample type and patient PIN.
▸ Remove 1 mL of whole blood from one of the 10 mL EDTA tubes that were collected for plasma.
▸ Transfer the 1 mL of whole blood into the 1.5 mL prelabelled polypropylene cryovial.
▸ Immediately store samples at −80°C.
▸ Fill out the electronic case report form to record the date the sample was taken and the Biobank ID numbers for each of the samples.
Plasma preparation: 2×10 mL EDTA tubes
▸ As the serum tubes require 20–30 min standing time before processing, begin with the plasma processing.
▸ Balance 2×10 mL EDTA tubes in the centrifuge and spin for 5 min at 1380 relative centrifugal force.
▸ Remove tubes from centrifuge and place on ice without shaking/inverting the tubes.
▸ Using the pipette, draw off the supernatant (upper layer) taking care not to disturb the interface, and transfer to a 15 mL polypropylene
tube on ice.
▸ Transfer the 1 mL aliquots of plasma into PRELABELED 1.5 mL polypropylene cryovials (anticipating 10 vials to be collected).
▸ Freeze the 10 cryovials of plasma at −80°C. Do not snap freeze (ie, do not dip in liquid nitrogen to freeze).
▸ The time taken from blood draw to freezing down the plasma samples at −80°C should not exceed 15 min.
▸ Fill out the electronic case report form to record the date the sample was taken and the Biobank ID numbers for each of the aliquots.
Serum preparation: 1×10 mL serum separator tube
▸ Let the serum 10 mL serum separator tube (with silica plug) stand at room temperature for 20–30 min to clot.
▸ Balance the tube in a refrigerated centrifuge and spin for 5 min at 1380 relative centrifugal force.
▸ Remove tube from centrifuge and place on ice without shaking/inverting the tube.
▸ Using a pipette, draw off the supernatant (upper layer) taking care not to disturb the interface and transfer to a 15 mL polypropylene
tube on ice.
▸ Transfer the 1 mL aliquots of serum into PRELABELED 1.5 mL polypropylene cryovials (anticipating 5 vials to be collected).
▸ Freeze the 5 cryovials of serum at −80°C. Do not snap freeze (ie, do not dip in liquid nitrogen to freeze).
▸ The time taken from blood draw to placing the serum samples in the −80°C freezer should not exceed 35–45 min. This includes the
20–30 min of standing time required for the sample to clot.
Fill out the electronic case report form to record the date the sample was taken and the Biobank ID numbers for each of the aliquots.
Number of sample aliquots:
We shall have the following numbers of aliquots per patient at the following visits:
Visit 2 (week 0).
1.5 mL cryovial containing 1 mL of whole blood for genotyping.
1.5 mL cryovials each containing 1 mL of plasma.
1.5 mL cryovials each containing 1 mL of serum.
Visit 4 (week 13), 7 (week 52) and 9 (week 78).
1.5 mL cryovials each containing 1 mL of plasma.
1.5 mL cryovials each containing 1 mL of serum.
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Kaiser normalisation will be used for rotation to simplify
and clarify the data structure. The Anderson-Rubin
method will be used for exporting uncorrelated scores
in order to perform MLM regression analyses, as for
other blood biomarkers.
The above analyses will be conducted on the ‘per
protocol population’.
CSF substudy
Study design
The CSF substudy will involve collection of CSF via
lumbar puncture (LP), for biomarker and inﬂammatory
marker analysis (box 2). Patients will undergo a LP prior
to start of the NILVAD study drug (ie, between the
screening and baseline assessment (week 0), and again
after treatment determination (week 78).
A paired serum albumin sample will also be drawn to
allow for calculation of the albumin CSF-serum ratio
(box 3). The ratio of albumin in CSF to serum is an
indicator of BBB integrity. An increased ratio can indi-
cate increased permeability and it has been demonstrated that AD pathology can lead to BBB dys-
function.38 While the underlying pathological mechan-
isms have yet to be fully elucidated, it is thought that
alterations to the BBB affects Aβ clearance and may con-
tribute to neuroinﬂammation seen in AD as a result of
ﬂuctuations in homeostasis.39
Samples will be collected, aliquoted and stored locally
at each study site initially, and then transported for ﬁnal
analysis to a central study site, before transfer to a
biobank for long-term storage. All samples will be stored
under speciﬁc conditions and coded for identiﬁcation
according to the protocol. An SOP will be adhered to
for collection and processing of the CSF sample and the
blood sample.
Inclusion/exclusion criteria
For this substudy, additional speciﬁc exclusion criteria
regarding contraindications to LP must be adhered to,
including (1) possible raised intracranial pressure, (2)
bleeding diathesis, including thrombocytopenia or treat-
ment with anticoagulant therapy.
Recruitment
All study sites, with the exclusion of those based in the
UK, Germany and Italy, will participate in the CSF
substudy.
Consenting process
In the case of the CSF substudy, consent by proxy is not
applicable and all participants must retain the capacity
to consent to undergo an LP. Of note, patients must
retain the capacity to consent to undergo a second LP at
the study end point.
Sample size calculations
Observed changes in CSF Aβ42 over a 78-week period
from a published study were used to calculate power for
Box 2 Standard operating procedure for lumbar puncture
(cerebrospinal fluid (CSF) collection and processing)
CSF sample collection and processing
The lumbar puncture will be carried out BETWEEN THE
SCREENING AND BASELINE VISIT (21-day window) and
TREATMENT TERMINATION, BETWEEN WEEK 78 AND WEEK 82.
The lumbar puncture should be performed ideally between 8:00
and 11:00.
▸ Local guidelines/routines for antiseptic cleansing and anaes-
thesia are to be followed.
▸ Position the patient in a reclining or sitting position with back
arched.
▸ Use a Spinal Needle Quincke Type Point 0.7×75 mm (75–
90 mm) for the LP.
▸ Insert the needle through the L3/L4 or L4/L5 interspace.
▸ In case of bleeding at the puncture site, the first 1 mL of CSF
should be discarded and this should be recorded.
Collect 10 mL of CSF from each participant. For CSF collec-
tion, use a POLYPROPYLENE TUBE ONLY
▸ (ie, 15 mL polypropylene tube).
▸ MIX the CSF gently by turning the tube upside down 3–4
times (cap on).
▸ Centrifuge the CSF in the polypropylene tube at 2000 g for
10 min at +4°C, to eliminate cells and debris.
▸ Transfer the centrifuged CSF into another sterile polypropylene
tube, being careful to avoid disturbing the pellet of cells and
debris at the end of the tube.
▸ Aliquot CSF in 1 mL aliquots into sterile 1.5 mL PRELABELED
POLYPROPYLENE CRYOVIALS with a screw cap.
▸ Place the tubes directly in a −80°C freezer. Do not snap freeze
(ie, do not dip in liquid nitrogen to freeze).
▸ Fill out the electronic case report form to record the date the
sample was taken and the Biobank ID numbers for each of the
aliquots.
▸ The patient should be allowed to rest for 30 min to 1 hour
after the lumbar puncture procedure.
Box 3 Standard operating procedure for paired serum
albumin sample collection and processing
Serum preparation
▸ Collect 5 mL of blood in a 10 mL serum separator tube (with
silica plug) and allow to stand at room temperature for 20–
30 min to clot.
▸ Balance the tube in a refrigerated centrifuge and spin for
5 min at 1380 relative centrifugal force.
▸ Remove tube from the centrifuge and place on ice without
shaking/inverting the tube.
▸ Using a pipette, draw off the supernatant (upper layer) taking
care not to disturb the interface, and transfer to a 10 mL poly-
propylene tube on ice.
▸ Transfer 1 mL aliquots of serum into PRELABELED 1.5 mL
polypropylene cryovials.
▸ Freeze the 5 cryovials of serum at −80°C. Do not snap freeze
(ie, do not dip in liquid nitrogen to freeze).
▸ Fill out the electronic case report form to record the date the
sample was taken and the Biobank ID numbers for each of the
aliquots.
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detecting potential decreases in CSF Aβ42 following
Nilvadipine treatment. The effect size calculations were
based on mean Aβ42 changes and associated variance
observed by Salloway and colleagues.40 The resulting
effect size was 0.67, which required a sample size of 98 for
detecting statistically signiﬁcant Aβ42 change from
baseline to week 78, with a power of 90% at α=0.05.
Data analysis
Analysis of CSF will be performed according to standar-
dised protocols. Aβ40, Aβ42, T and P 181 will be mea-
sured using a commercially available sandwich ELISA
(INNOTEST; Fujirebio Europe NV, Ghent, Belgium)
according to the manufacturer’s instructions.
The ratio between Aβ42 and Aβ40 for each patient will
be calculated as the concentration of Aβ42 divided by
the concentration of Aβ40 and multiplied by 100.41
First, an independent samples t-test will be used to
assess if there is a difference in Aβ-ratio between the two
groups at baseline, using α=0.05 as signiﬁcance level.
When the scores do not differ signiﬁcantly, an independ-
ent samples t-test will be used to assess if there is a differ-
ence in Aβ-ratio change between the two groups at week
78, using α=0.05 as signiﬁcance level.
The above analyses will be conducted on the ‘per
protocol population’.
Cerebral blood flow substudy
Study design
Participants will undergo additional measurements of
blood pressure (BP), cerebral autoregulation (CA) and
cerebral blood ﬂow (CBF) via MRI at baseline, week
26 and week 72.
Participants will be provided with a home blood pressure
monitor (HBPM, Microlife Watch BP Home) at the screen-
ing visit and requested to take their own BP readings twice
daily (morning and evening), after a 5 min period of relax-
ation, the week prior to their assessment visit at baseline,
week 26 and week 78, for assessment of BP variability.
Participants will be blinded to the BP readings (no result
visible on monitor screen) and measurements will be con-
ducted according to the European Society of Hypertension
guidelines.42 Participants will be requested to bring the
HBPM with them to the baseline visit (week 0) and week
26 and 78, to facilitate downloading of the BP data.
Additionally, at these visits, each participant will
undergo an MRI scan for measurement of CBF, using
arterial spin labelling (ASL) with multiple inﬂow times
(10 time points). This sequence allows for the recon-
struction of the blood ﬂow over time for each voxel.
A speciﬁc scanning protocol will be adhered to accord-
ing to the study protocol (box 4), including additional
sequences to measure, for instance, white matter integ-
rity and presence of microbleeds. Subsequently, all parti-
cipants will undergo CA measurements, again according
to the study protocol (box 5), measuring CBF velocity in
the middle cerebral artery, using transcranial Doppler.
In addition, near infrared spectroscopy (NIRS) will be
applied. During the measurement protocol, BP will be
measured continuously using servo-controlled ﬁnger
photoplethysmography (Finapres) and heartbeat will be
measured using ECG.
All measurements will be taken in the morning to
reduce the effect of diurnal variation in blood ﬂow.
Also, participants will have to refrain from intake of caf-
feine and alcohol, substances that can inﬂuence the
blood ﬂow measurement. Haematocrit level of every par-
ticipant will be measured on the morning of the scan,
since blood viscosity can inﬂuence the ASL measure-
ment. This will not reduce intraindividual variation.
Inclusion/exclusion criteria
Speciﬁc contraindications to MRI must be adhered to,
including (1) metal implants in situ and/or (2) suffer-
ing from claustrophobia. Patients who do not ﬁt the
MRI criteria can still participate in the CBF substudy, but
without the MRI.
Recruitment
This substudy will only be undertaken in one study site,
Nijmegen, in the Netherlands, to eliminate the variation
Box 4 Standard operating procedure for MRI acquisition
in the cerebral blood flow (CBF) substudy
Screening
▸ Make sure you have an empty home blood pressure monitor
(HBPM) that is set in Diagnostic mode and displays the right
time of day.
▸ At the end of the screening session, explain the use of the
HBPM and instruct the patient to start the home blood pres-
sure measurements the week before the CBF visit.
▸ Instruct the patient to bring the monitor with him/her on the
next visit.
Baseline
▸ Read out the data of the HBPM.
▸ Clear HBPM after checking data is saved correctly on the
computer.
▸ Give HBPM back to patient.
CBF MRI
▸ Take the patient to the Siemens Trio scanner at the Radiology
department.
▸ Together with the laboratory-assistant, instruct the patient and
make sure there is no metal on the body of the patient.
▸ Lie the patient in the scanner and put the MRI-compatible
blood pressure monitor in place.
▸ Scan the patient according to protocol:
Scan protocol
▸ T1-weighted anatomic scan (MP-RAGE) with 1 mm isotropic
resolution. Duration 5:47.
▸ Fluid-attenuated inversion recovery (FLAIR) (0.7×0.7×3 mm,
no gap). Duration 6:50.
▸ Susceptibility-weighted imaging (SWI) (1×1×1 mm). Duration
7:44.
▸ Diffusion tensor imaging (DTI) (2×2×2 mm). Duration 8:25.
▸ Arterial spin labelling (ASL) (3.4×3.4×4 mm). Duration 10:40.
TI 500–2750 ms, with increments of 250 ms.
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introduced by the use of different MRI scanners. Also, eli-
gible patients from another site (Arnhem, the Netherlands)
can be included in the substudy. These patients will not be
included in the separate randomisation process.
Sample size calculation
The total number of participants is based on the power
calculation computed on the primary efﬁcacy parameter,
CBF measured with ASL, as follows:
The primary variable of the study is a continuous vari-
able, the CBF, from independent control and experi-
mental subjects, with 50–50 distribution between the two
groups. There have been very few studies using CBF as
an outcome measure in an randomised controlled trial
(RCT), but a previous study where two groups were com-
pared detected a 25% difference.43 A recent RCT (N=27
vs N=31) detected a 36% change in CBF, using pulsed
ASL at 3 T.44 To detect a 15% difference in (regional)
CBF (using pulsed ASL at 3 T) between two groups, a
group size of 20 per group should be sufﬁcient, to be
able to reject the null hypothesis that the population
means of each group are equal with probability (power)
0.8.45 The type I error probability associated with the
test of this null hypothesis is a two-sided 0.05.
Data analysis
All analyses will be performed blind to participant
group.
Analysis of MRI data
Structural MRI scans will be processed using BET and
FAST, both packages of the publicly available image pro-
cessing software FSL 5.0 (http://www.fmrib.ox.ac.uk/
fsl/tbss/index.html) to identify grey matter (GM) and
white matter (WM), and CSF components on the
image.46 47 Total brain volume (TBV) will be calculated
as the sum of GM and WM volume (in mL), and intra-
cranial volume (ICV) as the sum of GM and WM plus
CSF. The TBV/ICV ratio will then be calculated as an
estimate of brain atrophy.
CBF will be calculated for the whole brain GM. The
data will be analysed using MLM, to test if the change in
whole brain GM CBF (maximum ﬂow) from baseline to
week 26 is different for the two intervention groups,
using α=0.05 as signiﬁcance level.
Brain atrophy and blood viscosity will be added as add-
itional model parameters. Using the multiple inﬂow
times, per voxel, the maximum ﬂow is calculated using
BASIL,48 another FSL package. To avoid brain atrophy
causing artiﬁcially low CBF values, partial volume correc-
tion will be used.
The above analyses will be conducted on the ‘per
protocol population’.
ETHICS AND DISSEMINATION
All four NILVAD Substudies will be conducted according
to Good Clinical Practice guidelines and in accordance
with the Declaration of Helsinki. All substudies have
been submitted for approval to the relevant indepen-
dent Ethics Committees in each participating country,
and have also been reviewed and will be continuously
monitored by the NILVAD Ethics Advisory Board, for
the duration of the main NILVAD study and substudies.
It is intended that all positive, neutral or negative
results for the substudies will be published in inter-
national peer-reviewed journals. Authorship and publica-
tion will be as per the agreed NILVAD study publication
policy.
SUBSTUDY STATUS
Enrolment for all substudies began with start of the
main NILVAD trial, in May 2013, and the recruitment
period continued until March 2015.
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Box 5 Standard operating procedure for Cerebral
Autoregulation as part of the cerebral blood flow (CBF)
substudy
Cerebral Autoregulation
▸ After a break, take the patient to the Haemodynamics
Laboratory at the Department of Geriatric Medicine (SKU,
Nijmegen).
▸ Instruct the patient and start the measurement software on the
computer.
▸ Put the headband in place, and then activate all the measure-
ment equipment
– Servo-controlled finger photoplethysmography (Finapres)
to continuously measure blood pressure.
– Transcranial Doppler (TCD) to measure CBF velocity in the
middle cerebral arteries. TCD-probes will be positioned on
the temporal bone.
– Near-infrared-spectroscopy (NIRS) to monitor changes in
cerebral cortical oxygenation. Optodes will be placed in a
specially designed headband.
Protocol
▸ Baseline measurements (5 min lying and 5 min sitting).
▸ Single sit-stand manoeuvres (2×2 min sitting, 1 min standing
+1×2 min sitting, 5 min standing).
▸ Repeated sit-stand manoeuvres (10 s sitting, 10 s standing for
5 min).
▸ Hyperventilation (30 s, 2 min recovery).
▸ CO2-inhalation (30 s 3%, 30 s 4%, 3 min 5%, 1 min recovery).
▸ Remove all equipment from the patient.
▸ End of entire measurement.
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